BioNTech Stock Falls 5% After BNT113 Trial Misses Endpoint

BioNTech shares dropped 5% on Tuesday after its Phase 2/3 clinical trial evaluating the investigational mRNA cancer therapy BNT113 in combination with Merck's Keytruda missed the progression-free survival endpoint in patients with advanced human papillomavirus-associated head and neck cancer. Despite the setback in progression-free survival, independent trial monitors recommended continuing the study to evaluate its remaining primary endpoint of overall survival, according to a Yahoo Finance report.

"The potential of mRNA cancer treatments lies in their ability to trigger immune responses that can provide long-lasting benefits and, ultimately, prolong patients' lives," said Prof. Özlem Türeci, Co-Founder and Chief Medical Officer at BioNTech.

Clinical Trial Design and Monitoring

The mid-to-late-stage trial assesses BNT113 paired with pembrolizumab (Keytruda) against standard-of-care treatments in recurrent or metastatic head and neck squamous cell carcinoma expressing HPV16. To maintain trial integrity and prevent potential bias, BioNTech confirmed in an SEC Form 6-K filing that company management currently lacks access to the ongoing data stream while the study proceeds toward its final overall survival evaluation.

Progression-free survival measures the length of time during and after the treatment of a disease, such as cancer, that a patient lives with the disease without it getting worse. In oncology research, missing a progression-free survival endpoint often forces a re-evaluation of a drug candidate's immediate efficacy, even if long-term survival metrics remain open for observation.

Market Valuation and Financial Performance

Following the disclosure, BioNTech SE (BNTX) traded at $87.71 per share, down 2.8% from its previous close of $90.20, according to Finnhub market data as of October 16, 2026. The downward movement reflects market sensitivity to clinical milestones for oncology-focused biotechnology firms relying on pipeline diversification beyond their foundational mRNA platforms.

The October 13 SEC filing formally updated investors on the BNT113 primary analysis ahead of the broader market reaction. As the company continues its pivot toward oncology applications, trial outcomes for pipeline candidates remain a primary driver of short-term stock volatility.